Skip to content
naulon

Not checkedNot checked for notices yet.

Formulation matters: LION nanoparticles improve RNA vaccine immunogenicity by containing systemic inflammation

Chandru Subramani, Tarani Kanta Barman

Molecular Therapy: Nucleic Acids · 2025

doi:10.1016/j.omtn.2025.102659 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The success of SARS-CoV-2 mRNA vaccines during the pandemic is driving the evolution of potential next-generation mRNA platforms, such as circular RNA and replicon RNA (repRNA), to prolong antigen expression, which could augment the immune response even at lower doses than conventional mRNA vaccines.1,2,3,4 While lipid nanoparticles (LNPs) are the most commonly used nanoformulation for delivering mRNA, they possess side effects. In contrast, the lipid-inorganic nanoparticle (LION) is emerging as an alternative to mitigate LNP-associated severe inflammation and enhance tolerability.

Abstract licence: CC BY-NC

References8

  1. 6.

7 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.